Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan-Reference-Cited by-同舟云学术

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

Published:2023-01-24 Issue:4 Volume:40 Page:1474-1493
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Ogura Takashi,Inoue Yoshikazu^ORCID,Azuma Arata^ORCID,Homma Sakae,Kondoh Yasuhiro,Tanaka Katsumi,Ochiai Kaori,Sugiyama Yukihiko,Nukiwa Toshihiro

Funder

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02411-y.pdf

Reference29 articles.

1. Kondoh Y, Suda T, Hongo Y, et al. Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir Res. 2022;23:24.

2. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190:773–9.

3. Homma S, Bando M, Azuma A, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56:268–91.

4. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68.

5. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan;Respiratory Investigation;2024-09

2. Safety, effectiveness, and usefulness of higher-dose tablets of generic pirfenidone in patients with IPF: a nationwide observational study in South Korea;Frontiers in Pharmacology;2024-08-09

3. Pamrevlumab for Idiopathic Pulmonary Fibrosis;JAMA;2024-08-06

4. Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis;Drugs - Real World Outcomes;2024-08-05

5. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases;Medicine;2024-07-12